

1        **Relationships between 25-Hydroxyvitamin D and Alpha-**  
2        **synucleinopathies: A Mendelian Randomization Study**

3        Fu-Jia Li<sup>1</sup>, Ru-Lin Geng<sup>1</sup>, Cheng Wen<sup>1</sup>, Kai-Xun Huang<sup>1</sup>, Dan-Yu Lin<sup>1</sup>, Zhong-Gui

4        Li<sup>1</sup>, Jie-Li Zhang<sup>1</sup>, Chuan-Ying Xu<sup>2</sup>, Wei Zhang<sup>2</sup>, Jie Zu<sup>2</sup>, Li-Guo Dong<sup>2</sup>, Wen-Xin

5        Wang<sup>1</sup>, Zhi-Jia Ruan<sup>1</sup>, Pei-Xiao Yin<sup>2</sup>, Chen-Yang Guan<sup>2</sup>, Gui-Yun Cui<sup>2\*</sup>, En-Xiang

6        Tao<sup>1\*</sup>

6

7        <sup>1</sup> Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University,

8        Shenzhen, Guangdong, China

9        <sup>2</sup> Department of Neurology, The Affiliated Hospital of Xuzhou Medical University,

10       Xuzhou, Jiangsu, China

11

12       Fu-Jia Li<sup>1</sup>, Ru-Lin Geng<sup>1</sup>, Cheng Wen<sup>1</sup>, These authors contributed equally to this

13       work and share first authorship.

14

15       **\* Corresponding Authors:**

16       Gui-Yun Cui

17 Department of Neurology, The Affiliated Hospital of Xuzhou Medical University

18 Xuzhou, Jiangsu, China

19 Tel: 8613852159170

20 Email: [cuiGuiyun-js@163.com](mailto:cuiGuiyun-js@163.com)

21

22 En-Xiang Tao

23 Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University,

24 Shenzhen, Guangdong, China

25 Tel: 8613500034942

26 Email: [taoex@mail.sysu.edu.cn](mailto:taoex@mail.sysu.edu.cn)

27

28 Word counts: 3,626

29

30

31

32

### 33 **Abbreviations**

34 25(OH)D: 25-hydroxyvitamin D

35 BWMR: Bayesian Weighted Mendelian randomization

36 CI: Confidence interval

37 cML-MA: Constrained maximum likelihood-model average

38 DLB: Dementia with Lewy bodies

39 GCI: Oligodendroglial cytoplasmic inclusion

40 IV: Instrumental variable

41 IVW: Inverse variance weighted

42 iRBD: Isolated rapid eye movement sleep behavior disorder

43 LD: Linkage disequilibrium

44 MR: Mendelian randomization

45 MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier

46 MR-RAPS: Mendelian randomization robust adjusted profile score

47 MSA: Multiple system atrophy

48 nSNPs: Number of instrumental variables

49 OPC: Impaired oligodendrocyte precursor cell

50 OR: Odds ratio

51 PD: Parkinson's disease

52 SNP: Single nucleotide polymorphism

53

54

55

56

57

58

59

60

61

62

63 **Abstract**

64 Background:

65 Alpha-synucleinopathies, including Parkinson's disease (PD), multiple system atrophy  
66 (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative diseases  
67 characterized by abnormal aggregation of alpha-synuclein. Isolated REM sleep  
68 behavior disorder (iRBD) is a prodromal stage of these disorders. While  
69 25-hydroxyvitamin D (25[OH]D) has been linked to PD in previous studies, its causal  
70 role remains unclear, and its relationship with iRBD, MSA, and DLB is rarely  
71 explored.

72 Objectives:

73 This study used Mendelian randomization (MR) to investigate the causal relationship  
74 between 25(OH)D and iRBD, PD, MSA, and DLB.

75 Methods:

76 GWAS data for 25(OH)D were sourced from the UK Biobank, and outcome data for  
77 PD were obtained from the latest FinnGen R12 database. Data for iRBD, PD onset  
78 age, PD clinical progression, MSA, and DLB were derived from a broader European  
79 population. The study had two steps: univariable MR (UVMR) using genome-wide IV  
80 selection as the primary analysis, with replication analyses using biological

81 function-based IV selection and sunlight exposure and vitamin D  
82 supplementation-related factors as exposures. Multivariable MR (MVMR) was then  
83 conducted to adjust for 13 covariates, testing the robustness of findings.

84 Results:

85 25(OH)D showed a significant protective effect on MSA across all UVMR (both  
86 primary and replication) and MVMR analyses. It also exhibited a nominal protective  
87 effect on PD in the Finnish population in primary UVMR analysis, but this was not  
88 replicated. No associations were found between 25(OH)D and iRBD, PD onset age,  
89 PD clinical progression, or DLB. Power analyses indicated insufficient sensitivity to  
90 detect weak effects of 25(OH)D on iRBD and DLB.

91 Conclusions:

92 MR analysis supports a protective role of 25(OH)D against MSA. While nominally  
93 protective for PD in the Finnish population, the effect was not robust. Weak effects on  
94 iRBD and DLB cannot be excluded.

95 Keywords:

96 25-hydroxyvitamin D, Alpha-synucleinopathy, Parkinson's disease, Multiple system  
97 atrophy, Dementia with Lewy bodies, Isolated REM sleep behavior disorder,  
98 Mendelian randomization

## 99 **Introduction**

100 Alpha-synucleinopathies, encompassing Parkinson's disease (PD), multiple system  
101 atrophy (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative  
102 disorders characterized by the misfolding and abnormal aggregation of  
103 alpha-synuclein<sup>1</sup>. These diseases result in progressive disability and mortality, with  
104 overlapping yet distinct clinical manifestations. PD presents with characteristic motor  
105 symptoms such as bradykinesia, resting tremor, and rigidity<sup>2</sup>. MSA is defined by  
106 severe autonomic dysfunction, often accompanied by parkinsonism or ataxia<sup>3</sup>. In  
107 contrast, DLB is marked by fluctuating cognitive decline, visual hallucinations, and  
108 parkinsonism<sup>4</sup>. Notably, isolated rapid eye movement sleep behavior disorder (iRBD),  
109 a condition characterized by the loss of muscle atonia during REM sleep and the  
110 presence of abnormal behaviors<sup>5</sup>, is recognized as a prodromal phase of  
111 alpha-synucleinopathies<sup>6</sup>. Despite the substantial burden on patients and healthcare  
112 systems, effective therapies for alpha-synucleinopathies remain scarce. Therefore,  
113 identifying modifiable risk factors is critical for prevention and improving patient  
114 outcomes.

115

116 Vitamin D, a fat-soluble steroid hormone, primarily exists in the body as  
117 25-hydroxyvitamin D (25[OH]D). It has been suggested to protect against

118 neurodegenerative diseases by maintaining calcium homeostasis, reducing oxidative  
119 stress, inhibiting inflammation, and preventing the aggregation of misfolded proteins  
120 (including alpha-synuclein)<sup>7,8</sup>, which are both involved in the pathogenesis of  
121 alpha-synucleinopathies. However, whether 25(OH)D provides clinical protection  
122 against alpha-synucleinopathies remains unclear.

123

124 In PD, most cross-sectional studies report lower 25(OH)D levels in patients compared  
125 to healthy controls<sup>9-11</sup>, but it is debated whether this reduction contributes to disease  
126 onset or results from disease progression. Immobility in PD could limit sunlight  
127 exposure, as indicated by reduced outdoor time, thereby decreasing vitamin D  
128 synthesis. Additionally, gastrointestinal dysfunction may impair absorption, both of  
129 which could potentially lead to lower 25(OH)D levels. Although cohort studies reduce  
130 reverse causation bias, their findings are inconsistent<sup>12-14</sup>. Additionally, clinical trials  
131 on vitamin D supplementation have not consistently shown PD symptom  
132 improvement<sup>15-17</sup>. Research on vitamin D in MSA<sup>18,19</sup> and DLB<sup>20</sup> is even more limited,  
133 hindered by small sample sizes and methodological issues, such as cross-sectional  
134 designs and inadequate control for confounders like outdoor time and dietary vitamin  
135 D intake. These limitations challenge the reliability and generalizability of existing  
136 findings.



137

138 To develop effective interventions, identifying risk factors within the causal pathway  
139 of the disease is essential. Mendelian randomization (MR) provides a robust method  
140 for causal inference by minimizing confounding bias and reverse causation. The  
141 limitations of the existing MR study, however, highlight the need for further research.  
142 In 2017, Susanna C. Larsson and colleagues used MR to examine the relationship  
143 between 25(OH)D and PD but found no causal link<sup>21</sup>. They partly attributed the  
144 inconclusive results to the small effect size of 25(OH)D and the limited number of  
145 instrumental variables (IVs), which reduced statistical power.

146

147 With the availability of large genome-wide association study (GWAS) datasets and  
148 advancements in MR methods, this study aims to comprehensively investigate the  
149 relationships between 25(OH)D levels and iRBD, PD, age at PD onset, PD clinical  
150 progression, MSA, and DLB.

151

## 152 **Method**

### 153 **1. Study Design**

154 Our study consisted of two steps. Step one involved univariable MR (UVMR)  
155 analysis, where we selected IVs across the whole genome to investigate the effects of  
156 25(OH)D on the following outcomes: iRBD, PD, age at PD onset, progression of 21  
157 clinical PD phenotypes, MSA, and DLB. This served as the primary analysis.  
158 Outcomes showing nominal statistical significance with 25(OH)D ( $P < 0.05$ )  
159 underwent further replication analysis, with biological function-based IV selection  
160 and sunlight exposure and vitamin D supplementation-related factors as exposures. In  
161 step two, outcomes with consistent results in primary and replication UVMR analyses  
162 were further included in the MVMR analysis to adjust for covariates. The study  
163 strictly adhered to the three core assumptions<sup>22</sup> of MR analysis and followed the  
164 STROBE-MR guidelines<sup>23</sup> (**Table S2**).

165

## 166 **2. Data Source**

167 We obtained summary-level GWAS statistics from recent large-scale studies of  
168 European populations. To minimize sample overlap, exposure and outcome data were  
169 derived from different cohorts. Ethical approvals were obtained from each  
170 participating cohort, so no additional ethical approvals or informed consents were  
171 required. The composition of GWAS data cohorts, the content of questionnaires used

172 to define clinical characteristics, the specific methods and kits used for laboratory  
173 measurements, and the diagnostic criteria for diseases can be found in **Table S1**.

174

## 175 **2.1 Exposures**

176 As in previous studies<sup>24-26</sup>, we used the most recent 25(OH)D GWAS dataset, which  
177 is based on the UK Biobank population (n = 417,580)<sup>27</sup>. Serum 25(OH)D  
178 concentrations were measured using a chemiluminescence immunoassay (Diasorin  
179 Liaison®), which covered 25(OH)D3 and 25(OH)D2. Individuals with total  
180 concentrations outside the range of 10–375 nmol/L were excluded. The median, mean,  
181 and interquartile range of 25(OH)D concentrations were 47.9, 49.6, and 33.5–63.2  
182 nmol/L, respectively.

183

184 Most vitamin D is synthesized in the skin through UV exposure, with only ~20%  
185 obtained from dietary intake<sup>28</sup>. Similar to previous observational studies<sup>11,29</sup>, our study  
186 also considered characteristics related to sunlight exposure and vitamin D  
187 supplementation as exposure factors. The GWAS data for these characteristics were  
188 derived from the UK Biobank and included variables such as time spend outdoors in  
189 summer (n = 419,314) and winter (n = 364,465), skin color (n = 456,692), use of sun

190 protection (n = 459,416), use of vitamin D supplements (cases/controls =  
191 17,879/442,472), and non-use of any vitamin or mineral supplements (cases/controls  
192 = 144,656/315,695). These data were self-reported through touchscreen  
193 questionnaires.

194

## 195 **2.2 Covariates**

196 The "2024 Consensus Statement on Vitamin D Status Assessment and  
197 Supplementation"<sup>30</sup> highlighted key factors influencing vitamin D levels. If genetic  
198 IVs for 25(OH)D are strongly associated with these factors, they may directly impact  
199 outcomes via non-25(OH)D pathways, introducing horizontal pleiotropy and biasing  
200 the results. To mitigate this, we identified 13 covariates, grouped them into three sets,  
201 and sequentially incorporated them into MVMR analyses to minimize horizontal  
202 pleiotropy and strengthen the reliability of our causal inference. The covariate data  
203 were mainly derived from the UK Biobank. Set 1 included lifestyle and  
204 socioeconomic factors: body mass index, smoking initiation, alcohol intake frequency,  
205 levels of moderate-to-vigorous physical activity, and years of education. Set 2  
206 comprised vitamin D metabolism-related markers: alanine aminotransferase,  
207 creatinine, and parathyroid hormone levels. Set 3 included chronic health conditions:

208 hypertension, type 2 diabetes, atherosclerotic cardiovascular diseases, stroke, and  
209 gastrointestinal or abdominal diseases.

210

### 211 **2.3 Outcomes**

212 To avoid sample overlap, given that the exposure data in this study were sourced from  
213 the UK Biobank, we did not use datasets curated by Mike A. Nalls (December 2019)<sup>31</sup>  
214 or Jonggeol Jeffrey Kim (January 2024)<sup>32</sup>. Instead, we used the latest PD GWAS data  
215 from the FinnGen R12 database (<https://r12.finnngen.fi/>, November 2024), which  
216 included 5,861 cases and 494,487 controls. PD diagnoses were based on ICD-10  
217 (G20), ICD-9 (3320A), and ICD-8 (34200) codes. Similarly, Tao Wang et al.  
218 followed the same data selection strategy under similar circumstances<sup>33</sup>. The PD  
219 age-at-onset dataset was obtained from the International Parkinson's Disease  
220 Genomics Consortium<sup>34</sup>. Age at onset was defined based on patient-reported initial  
221 parkinsonian motor symptoms, or, if unavailable, the age of diagnosis was used as a  
222 proxy. The datasets on PD clinical progression included 12 longitudinal cohorts of PD  
223 patients recruited from North America, Europe, and Australia<sup>35</sup>. These datasets  
224 included 21 clinical features of disease progression, covering changes in staging,  
225 worsening motor symptoms, reduced daily functioning, aggravated non-motor  
226 symptoms, cognitive decline, new motor complications, depression, impaired smell,

227 increased constipation, and sleep disturbances. The iRBD GWAS data, aggregated by  
228 Lynne Krohn’s team in December 2022, included 1,061 cases and 8,386 controls from  
229 cohorts in France, Canada, Italy, the UK, and other European countries<sup>36</sup>. Cases were  
230 identified by the International RBD Study Group, diagnosed according to the  
231 International Classification of Sleep Disorders (2nd or 3rd Edition), and confirmed via  
232 video-polysomnography. MSA GWAS data, aggregated by Ruth Chia’s team in July  
233 2024, included 888 cases and 7,128 controls recruited from 20 centers across North  
234 America and Europe<sup>37</sup>. Cases were diagnosed as clinically probable or pathologically  
235 confirmed using the Gilman consensus criteria. DLB GWAS data, also aggregated by  
236 Ruth Chia’s team in February 2021, comprised 2,591 cases and 4,027 controls<sup>38</sup>.  
237 Participants were recruited from 44 centers in Europe and North America, with  
238 controls drawn from the Welllderly cohort and the National Institute on Aging. DLB  
239 cases were either autopsy-confirmed or clinically probable.

240

### 241 **3. Genetic Instrument Selection**

242 In this study, IVs were selected using two approaches. First, genome-wide IV  
243 selection: single nucleotide polymorphisms (SNPs) significantly associated with the  
244 exposure ( $P < 5 \times 10^{-8}$ ) across the whole genome were chosen. If this threshold  
245 yielded insufficient IVs, a more lenient threshold ( $P < 5 \times 10^{-6}$ ) was applied,

246 selecting IVs for iRBD, PD age at onset, progression of PD symptoms, MSA, DLB,  
247 and vitamin D supplementation. Second, biological function-based IV selection: IVs  
248 were selected from genes involved in vitamin D metabolism, including GC, CYP2R1,  
249 DHCR7, and CYP24A1<sup>39,40</sup>.

250

251 The  $R^2$  value was used to assess the proportion of variance in exposure explained by  
252 each SNP, while the F-statistic ensured instrument strength (retaining only SNPs with  
253  $F > 10$ ). SNPs in linkage disequilibrium ( $r^2 > 0.001$ , window size 10,000 kb) or with  
254 effect allele frequencies below 0.01 were excluded. To meet MR independence  
255 assumptions, SNPs directly associated with the outcome were identified and excluded  
256 according to the LDtrait database (<https://ldlink.nih.gov/?tab=ldtrait>).

257

#### 258 **4. Mendelian Randomization**

259 For the UVMR analyses, we used multiple analytical models. The inverse variance  
260 weighted (IVW)<sup>41</sup> method served as the primary model due to its high statistical  
261 power when all instrumental variables are valid, though it is sensitive to heterogeneity  
262 and pleiotropy. To enhance robustness, we applied five secondary models:  
263 MR-Egger<sup>42</sup> and weighted median<sup>43</sup> methods, which provide reliable estimates in the

264 presence of pleiotropy or invalid instruments, albeit with lower power; the constrained  
265 maximum likelihood-model average (cML-MA)<sup>44</sup> method, robust against pleiotropy;  
266 the robust adjusted profile score (MR-RAPS)<sup>45</sup> method, effective for weak  
267 instruments; and Bayesian weighted MR (BWMR)<sup>46</sup>, which uses Bayesian weighting  
268 to address pleiotropy and accounts for polygenicity, making it suitable for analyzing  
269 complex traits or diseases. These methods complemented each other and contributed  
270 to the reliability and robustness of the results. MR results were reported as odds ratios  
271 (OR) with 95% confidence intervals (CI), representing the effect of a genetically  
272 determined unit change in exposure on outcome risk. For continuous exposures, the  
273 OR reflects the change in risk per one standard deviation increase; for binary  
274 exposures, it represents the risk ratio between exposed and non-exposed groups.

275

276 In the UVMR analyses, several sensitivity analyses were performed to ensure  
277 robustness: (1) Results from genome-wide IV selection served as the primary UVMR  
278 analysis, while replication analyses used biological function-based IV selection and  
279 exposures such as sunlight exposure and vitamin D supplementation for mutual  
280 validation; (2) Effect estimates were obtained using one primary model and five  
281 secondary models suited to different assumptions; (3) Cochran's Q-statistic was  
282 applied to evaluate heterogeneity in the IVW results; (4) Potential horizontal  
283 pleiotropy was assessed using the MR-Egger intercept p-value<sup>42</sup> and the Mendelian



284 Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) global test<sup>47</sup>; (5)  
285 Outliers among IVs were identified using MR-PRESSO and MR-Radial (Radial-IVW  
286 and Radial-Egger tests, with  $P < 0.05$  indicating outliers), and MR analyses were  
287 repeated after removing identified outliers; (6) Leave-one-out analyses were  
288 conducted to determine whether the results were driven by specific SNPs; (7) Finally,  
289 the tool <https://shiny.cnsgenomics.com/mRnd/> was used to calculate the minimum  
290 detectable causal effect size at 80% statistical power in the MR analyses<sup>48</sup>.

291

292 To reduce bias from reverse causality, we adopted the following strategies: (1)  
293 Excluding IVs significantly associated with the outcome; (2) Testing the causal  
294 direction using the Steiger test<sup>49</sup>; and (3) Conducting reverse MR analyses.

295

296 In the MVMR analyses, causal effects were estimated using the MVMR-IVW, and  
297 MVMR-Egger methods, with horizontal pleiotropy evaluated based on whether the  
298 MR-Egger intercept significantly deviated from zero. When no pleiotropy was  
299 detected, the MVMR-IVW method was used as the primary estimator; if pleiotropy  
300 was present, the results primarily relied on the MVMR-Egger method<sup>42</sup>.

301

302 All analyses were two-sided tests performed using R version 4.4.1. Relevant R  
303 packages included TwoSampleMR, MendelianRandomization, MR-PRESSO,  
304 RadialMR, MR.RAPS, MRcML, and BWMR.

305

## 306 **Results**

### 307 **1. Primary UVMR analysis results**

308 After quality control and removing SNPs in linkage disequilibrium, 115 SNPs  
309 strongly associated with 25(OH)D were retained as candidate IVs (**Table S3**). A  
310 search on the LDtrait platform identified six SNPs directly associated with  
311 alpha-synucleinopathies (**Table S4**), which were excluded. Among the remaining 109  
312 SNPs, 104, 104, 97, 97, and 98 were successfully harmonized with the datasets for  
313 iRBD, PD, age at onset of PD, MSA, and DLB, respectively. These SNPs explained  
314 approximately 4.28%-4.42% of the variance in 25(OH)D levels, and all F-statistics  
315 exceeded 10, confirming that the MR results were not affected by weak instruments  
316 (**Table 1**).

317

318 UVMR analysis showed a significant protective effect of higher 25(OH)D levels on  
319 MSA (OR [95% CI]: 0.598 [0.421, 0.851],  $P = 0.004$ ,  $P_{\text{FDR}} = 0.021$ , **Figure 2**).

320 This finding was supported by the primary analysis model (IVW) and four secondary  
321 models (MR Egger, Weighted median, MR-RAPS, and BWMR), with the cML-MA  
322 model showing consistent effect direction despite not reaching statistical significance.  
323 MR-PRESSO identified no significant outliers among the 97 instrumental variables,  
324 while MR-Radial detected 1 potential outlier (**Table S5**). Reanalysis excluding this  
325 outlier produced robust results (**Table S6**). Steiger directionality tests and reverse MR  
326 (**Table S9, 10**) supported the causal direction, and Cochran's Q test indicated no  
327 heterogeneity. MR-Egger regression and the MR-PRESSO global test showed no  
328 evidence of horizontal pleiotropy (**Table S7**). Leave-one-out analysis confirmed that  
329 results were not driven by individual SNPs (**Table S8**).

330

331 MR analysis also suggested a nominal protective effect of higher 25(OH)D levels on  
332 PD (OR [95% CI]: 0.867 [0.758, 0.991],  $P = 0.036$ ,  $P_{FDR} = 0.091$ , **Figure 2**),  
333 supported by the IVW, MR-RAPS, and BWMR models, with consistent effect  
334 directions across all six models. MR-PRESSO detected no significant outliers among  
335 the 104 instrumental variables, while MR-Radial identified 7 potential outliers (**Table**  
336 **S5**). Reanalysis excluding these outliers showed robust results (**Table S6**). Sensitivity  
337 analyses confirmed the findings were consistent in direction and unaffected by  
338 heterogeneity or horizontal pleiotropy (**Table S7-10**).

339

340 However, UVMR analysis did not provide evidence of an effect of 25(OH)D levels on  
341 age at onset of PD, PD clinical progression (**Table S6**), or the risk of iRBD and DLB  
342 (**Figure 2**). These results remained robust in sensitivity analyses (**Table S7-10**).  
343 Statistical power calculations suggested that UVMR analysis might not have been  
344 sufficient to detect weaker effects of 25(OH)D on iRBD and DLB (**Table 1**).

345

## 346 **2. Replication UVMR analysis results**

347 We selected eight SNPs from four key genes involved in vitamin D metabolism as  
348 IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728;  
349 CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, **Table S11**) and  
350 conducted UVMR analysis again. The results confirmed that 25(OH)D remains a  
351 protective factor for MSA (OR [95% CI]: 0.562 [0.366, 0.863],  $P = 0.008$ , **Figure 3A**).  
352 However, its effect on PD was no longer significant. We also examined the  
353 relationships between sunlight exposure, vitamin D supplementation-related factors,  
354 and MSA or PD. Darker skin and "non-use of vitamin or mineral supplements" were  
355 identified as risk factors for MSA, while vitamin D supplementation had a protective  
356 effect on MSA (**Figure 3B**, **Table S12**). No evidence was found to support an

357 influence of sunlight exposure or vitamin D supplementation on PD risk. These  
358 findings remained robust in sensitivity analyses (**Table S13**).

359

### 360 **3. MVMR analysis results**

361 After adjusting for lifestyle and socioeconomic factors (body mass index, smoking,  
362 alcohol intake frequency, moderate-to-vigorous physical activity levels, and years of  
363 education), vitamin D metabolism-related markers (alanine aminotransferase,  
364 creatinine, and parathyroid hormone levels), and chronic health conditions  
365 (hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, stroke, and  
366 gastrointestinal or abdominal disease), the protective effects of 25(OH)D on MSA  
367 remained significant (**Figure 4**). Sensitivity analyses suggested that some results were  
368 mildly influenced by heterogeneity (**Table S14**), likely due to the large number of  
369 instrumental variables used. None of the results were affected by horizontal pleiotropy  
370 (**Table S14**).

371

### 372 **Discussion**

373 This is the first MR study comprehensively exploring the relationship between serum  
374 25(OH)D levels and alpha-synucleinopathies. Our findings provide evidence for the

375 protective effect of 25(OH)D on MSA, which remained robust across primary and  
376 replication UVMR analyses and after adjusting for 13 covariates in MVMR analysis.  
377 Additionally, 25(OH)D showed a nominal protective effect on PD in the Finnish  
378 population, though this lacked sufficient robustness. The possibility of a weak effect  
379 on iRBD or DLB cannot be ruled out.

380

### 381 **1. Declined 25(OH)D Levels in PD: Risk Factor or Consequence?**

382 PD is the second most common neurodegenerative disorder and the most prevalent  
383  $\alpha$ -synucleinopathy. The relationship between 25(OH)D and PD remains controversial.  
384 Most cross-sectional studies have reported significantly lower 25(OH)D levels in PD  
385 patients compared to controls<sup>9-11</sup>. However, this decrease may reflect disease  
386 progression rather than causality, potentially influenced by reduced sunlight exposure  
387 due to impaired mobility or vitamin D malabsorption caused by gastrointestinal  
388 symptoms. In contrast, cohort studies are less affected by reverse causation but yield  
389 inconsistent findings. While studies in Finnish and UK Biobank cohorts support a  
390 protective role of 25(OH)D against PD<sup>12,13</sup>, research from the United States found no  
391 significant association<sup>14</sup>. Variability in genetic background, geographic factors, and  
392 behavioral differences across cohorts likely contributes to these discrepancies.

393

394 MR analysis offers a robust approach to address confounding and reverse causation  
395 compared to observational studies. In 2017, Susanna C. Larsson utilized small GWAS  
396 data in an MR analysis of 25(OH)D and PD but found no significant association<sup>21</sup>.  
397 Using larger GWAS datasets, our study identified a nominal protective effect of  
398 25(OH)D against PD in the Finnish population. However, this finding lacked  
399 robustness in replication analyses. We speculate that the protective effect of 25(OH)D  
400 on PD may be modest, and the limited statistical power of replication analyses might  
401 have hindered the detection of such a weak effect, which could also explain the null  
402 results in Larsson's study.

403

404 Notably, a 2011 cohort study reported that 25(OH)D levels did not decline with PD  
405 progression<sup>50</sup>. Similarly, our reverse MR analysis showed that PD status does not  
406 significantly affect 25(OH)D levels. Furthermore, advancing Hoehn and Yahr stages,  
407 worsening motor symptoms, and increased severity of constipation were not  
408 associated with changes in 25(OH)D levels. These findings provide additional  
409 evidence supporting the hypothesis that reduced 25(OH)D levels are a risk factor for  
410 PD rather than a consequence of disease progression.

411

412 **2. 25(OH)D and MSA: Present Evidence and Potential Mechanisms**

413 MSA is at least ten times less prevalent than PD but progresses more rapidly, often  
414 causing severe disability within 5–6 years and death within 10 years of symptom  
415 onset<sup>3</sup>. Due to its rarity, only two cross-sectional studies have investigated the  
416 relationship between 25(OH)D levels and MSA, both reporting significantly lower  
417 levels in MSA patients compared to controls<sup>18,19</sup>. However, these studies did not  
418 adjust for confounders, limiting their reliability. Our MR analysis supports a causal  
419 relationship between lower 25(OH)D levels and increased MSA risk. This conclusion  
420 was robust across primary and replication UVMR analyses and remained consistent  
421 after comprehensive covariate adjustment using MVMR. The MR findings align with  
422 trends observed in previous studies but should be interpreted cautiously due to  
423 population differences. Observational studies were predominantly conducted in Asian  
424 cohorts, while our MR analysis used European data. Notably, genetic differences and  
425 subtype distributions (MSA-P vs. MSA-C) between European and Asian MSA  
426 patients<sup>3</sup> may influence results. Prospective observational studies in European  
427 populations are needed to validate these findings.

428

429 Vitamin D can cross the blood-brain barrier<sup>51</sup>, and its receptors are widely expressed  
430 in neurons and glial cells<sup>52</sup>, providing a biological basis for its potential role in MSA.  
431 Research suggests that vitamin D exerts neuroprotective effects in neurodegenerative  
432 diseases by suppressing immune-inflammatory responses, reducing oxidative stress,



433 enhancing autophagy, and promoting neurotrophic factor expression<sup>7,53</sup>. These  
434 mechanisms may also explain its protective role in MSA, which shares overlapping  
435 pathogenic pathways with other neurodegenerative disorders<sup>3,54</sup>. Additionally,  
436 25(OH)D may also confer protective effects against MSA through distinct  
437 mechanisms. MSA is characterized by oligodendroglial cytoplasmic inclusions (GCIs)  
438 rich in aggregated  $\alpha$ -synuclein, along with extensive myelin degeneration and  
439 oligodendrocyte dysfunction (impaired oligodendrocyte precursor cell [OPC]  
440 maturation, remyelination defects, and reduced neuroprotective functions)<sup>54-58</sup>. In  
441 vitro studies demonstrate that vitamin D reduces  $\alpha$ -synuclein oligomer aggregation  
442 and associated neurocytotoxicity in neurons<sup>8</sup>, though its potential effect on  
443  $\alpha$ -synuclein deposition in oligodendrocytes remains unclear. Additionally, vitamin D  
444 promotes remyelination and neurorepair by enhancing OPC differentiation and  
445 creating a protective microenvironment<sup>59-62</sup>, suggesting its therapeutic potential in  
446 MSA.

447

### 448 **3. Clinical Implications**

449 (1) MSA progresses rapidly, with no disease-modifying treatments or effective  
450 symptomatic management. Reducing its incidence is essential to alleviating the  
451 disease burden. While risk factors for MSA were previously unknown, our study is

452 the first to identify 25(OH)D as a protective factor. Given the high prevalence of  
453 vitamin D deficiency<sup>63</sup>, widespread vitamin D supplementation may have the  
454 potential to significantly reduce MSA incidence. (2) Our findings highlight the need  
455 for multicenter prospective studies to confirm the protective effect of 25(OH)D on  
456 MSA. Further exploration is warranted to determine if this effect extends to patients  
457 with iRBD and early autonomic dysfunction, prodromal stages of MSA<sup>6</sup>. (3) Our  
458 study provides additional evidence that reduced 25(OH)D levels are a risk factor for  
459 PD rather than a consequence of disease progression, requiring further follow-up  
460 studies.

461

#### 462 **4. Limitations**

463 (1) Our study population was European, which may limit the generalizability of the  
464 findings. While we identified a protective effect of 25(OH)D against MSA, previous  
465 supporting observational studies were conducted in Asian populations. Future  
466 observational studies in European populations are needed to validate this conclusion.  
467 (2) The limited sample size prevented us from determining whether the lack of  
468 associations between 25(OH)D, iRBD risk, PD progression, and DLB risk reflects  
469 insufficient statistical power or a true absence of association. Larger GWAS datasets  
470 are needed for future MR analyses. (3) Due to data constraints, we could not assess

471 whether 25(OH)D influences MSA risk in patients with iRBD or early autonomic  
472 dysfunction, nor its effects on MSA progression. These areas warrant further study.

473

## 474 **5. Conclusions**

475 In summary, our study identifies a protective role of 25(OH)D against MSA.

476 Although 25(OH)D showed a nominal protective effect on PD in the Finnish

477 population, the result lacked robustness. Potential weak effects on iRBD and DLB

478 cannot be excluded.

479

## 480 **Acknowledgement**

481 FJL, RLG, and CW designed research; FJL, RLG, CW, GYC, EXT, and the other

482 authors (KXH, DYL, ZGL, JLZ, CYX, WZ, JZ, LGD, WXW, ZJR, PXY, CYG)

483 conducted research; GYC, EXT, and the other authors (KXH, DYL, ZGL, JLZ, CYX,

484 WZ, JZ, LGD, WXW, ZJR, PXY, CYG) provided essential materials; FJL, RLG, and

485 CW analyzed data; and FJL, RLG, and CW wrote the paper. GYC and EXT had

486 primary responsibility for final content. All authors read and approved the final

487 manuscript.

488

489 **Conflict of Interest**

490 The authors have no conflicts of interest relevant to the content of this article.

491

492 **Funding**

493 This study was funded by Shenzhen Science and Technology Program

494 (JCYJ20220818102206014), National Natural Science Foundation of China

495 (82271454), the Futian Healthcare Research Project (FTWS2022010), the District

496 Key Specialty Funds / Department of Neurology (QZDZK-202410), and the Hospital

497 Key Discipline Funds / Department of Neurology (YZDXKJF-202017).

498

499 **Data Sharing**

500 The GWAS data sources used in this study are detailed in the Methods section and

501 Table S1. Code book, and analytic code will be made available upon request pending.

502

503

504

## 505 Reference

- 506 1. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease,  
507 dementia with Lewy bodies, and multiple system atrophy. *Annals of the New York*  
508 *Academy of Sciences*. 2000;920:16-27. doi:10.1111/j.1749-6632.2000.tb06900.x
- 509 2. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nature reviews Disease*  
510 *primers*. Mar 23 2017;3:17013. doi:10.1038/nrdp.2017.13
- 511 3. Poewe W, Stankovic I, Halliday G, et al. Multiple system atrophy. *Nature*  
512 *reviews Disease primers*. Aug 25 2022;8(1):56. doi:10.1038/s41572-022-00382-6
- 513 4. Prasad S, Katta MR, Abhishek S, et al. Recent advances in Lewy body dementia:  
514 A comprehensive review. *Disease-a-month : DM*. May 2023;69(5):101441.  
515 doi:10.1016/j.disamonth.2022.101441
- 516 5. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder.  
517 *Nature reviews Disease primers*. Aug 30 2018;4(1):19.  
518 doi:10.1038/s41572-018-0016-5
- 519 6. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society  
520 Criteria for the Diagnosis of Multiple System Atrophy. *Movement disorders : official*  
521 *journal of the Movement Disorder Society*. Jun 2022;37(6):1131-1148.  
522 doi:10.1002/mds.29005
- 523 7. Wang W, Li Y, Meng X. Vitamin D and neurodegenerative diseases. *Heliyon*. Jan  
524 2023;9(1):e12877. doi:10.1016/j.heliyon.2023.e12877
- 525 8. Zhang Y, Ji W, Zhang S, et al. Vitamin D Inhibits the Early Aggregation of  
526  $\alpha$ -Synuclein and Modulates Exocytosis Revealed by Electrochemical Measurements.  
527 *Angewandte Chemie (International ed in English)*. Jan 3 2022;61(1):e202111853.  
528 doi:10.1002/anie.202111853
- 529 9. Suzuki M, Yoshioka M, Hashimoto M, et al. 25-hydroxyvitamin D, vitamin D  
530 receptor gene polymorphisms, and severity of Parkinson's disease. *Movement*  
531 *disorders : official journal of the Movement Disorder Society*. Feb 2012;27(2):264-71.  
532 doi:10.1002/mds.24016
- 533 10. Wang L, Evatt ML, Maldonado LG, et al. Vitamin D from different sources is  
534 inversely associated with Parkinson disease. *Movement disorders : official journal of*  
535 *the Movement Disorder Society*. Apr 2015;30(4):560-6. doi:10.1002/mds.26117
- 536 11. Zhou Z, Zhou R, Zhang Z, Li K. The Association Between Vitamin D Status,  
537 Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A  
538 Systematic Review and Meta-Analysis. *Medical science monitor : international*

- 539 *medical journal of experimental and clinical research*. Jan 23 2019;25:666-674.  
540 doi:10.12659/msm.912840
- 541 12. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M.  
542 Serum vitamin D and the risk of Parkinson disease. *Archives of neurology*. Jul  
543 2010;67(7):808-11. doi:10.1001/archneurol.2010.120
- 544 13. Veronese N, Nova A, Fazia T, et al. Contribution of Nutritional, Lifestyle, and  
545 Metabolic Risk Factors to Parkinson's Disease. *Movement disorders : official journal*  
546 *of the Movement Disorder Society*. Jul 2024;39(7):1203-1212.  
547 doi:10.1002/mds.29778
- 548 14. Shrestha S, Lutsey PL, Alonso A, Huang X, Mosley TH, Jr., Chen H. Serum  
549 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.  
550 *Movement disorders : official journal of the Movement Disorder Society*. Jul  
551 2016;31(7):972-8. doi:10.1002/mds.26573
- 552 15. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind,  
553 placebo-controlled trial of vitamin D supplementation in Parkinson disease. *The*  
554 *American journal of clinical nutrition*. May 2013;97(5):1004-13.  
555 doi:10.3945/ajcn.112.051664
- 556 16. Bytowska ZK, Korewo-Labelle D, Berezka P, et al. Effect of 12-Week  
557 BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain  
558 Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites.  
559 *International journal of molecular sciences*. Jun 15  
560 2023;24(12)doi:10.3390/ijms241210200
- 561 17. Hiller AL, Murchison CF, Lobb BM, O'Connor S, O'Connor M, Quinn JF. A  
562 randomized, controlled pilot study of the effects of vitamin D supplementation on  
563 balance in Parkinson's disease: Does age matter? *PloS one*. 2018;13(9):e0203637.  
564 doi:10.1371/journal.pone.0203637
- 565 18. Guo Y, Zhuang XD, Xian WB, et al. Serum Klotho, vitamin D, and homocysteine  
566 in combination predict the outcomes of Chinese patients with multiple system  
567 atrophy. *CNS neuroscience & therapeutics*. Aug 2017;23(8):657-666.  
568 doi:10.1111/cns.12711
- 569 19. Ogura H, Hatip-Al-Khatib I, Suenaga M, et al. Circulatory 25(OH)D and  
570 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and  
571 Parkinson's disease patients. *eNeurologicalSci*. Dec 2021;25:100369.  
572 doi:10.1016/j.ensci.2021.100369
- 573 20. Janse A, van de Rest O, de Groot L, Witkamp RF. The Association of Vitamin D  
574 Status with Mild Cognitive Impairment and Dementia Subtypes: A Cross-Sectional

- 575 Analysis in Dutch Geriatric Outpatients. *Journal of Alzheimer's disease : JAD*.  
576 2023;91(4):1359-1369. doi:10.3233/jad-220732
- 577 21. Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role  
578 for vitamin D in Parkinson's disease: A Mendelian randomization study. *Movement*  
579 *disorders : official journal of the Movement Disorder Society*. Aug  
580 2017;32(8):1249-1252. doi:10.1002/mds.27069
- 581 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation  
582 studies: a guide, glossary, and checklist for clinicians. *BMJ (Clinical research ed)*. Jul  
583 12 2018;362:k601. doi:10.1136/bmj.k601
- 584 23. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting  
585 of observational studies in epidemiology using mendelian randomisation  
586 (STROBE-MR): explanation and elaboration. *BMJ (Clinical research ed)*. Oct 26  
587 2021;375:n2233. doi:10.1136/bmj.n2233
- 588 24. Konzok J, Baumeister SE, Winkler TW, Leitzmann MF, Baurecht H. Effect of  
589 25-hydroxyvitamin D levels on the internalising dimension as a transdiagnostic risk  
590 factor: Mendelian randomisation study. *The British journal of psychiatry : the journal*  
591 *of mental science*. Jun 2023;222(6):257-263. doi:10.1192/bjp.2023.32
- 592 25. Lee KJ, Kim H, Lee SJ, et al. Causal Effect of the 25-Hydroxyvitamin D  
593 Concentration on Cerebral Small Vessel Disease: A Mendelian Randomization Study.  
594 *Stroke*. Sep 2023;54(9):2338-2346. doi:10.1161/strokeaha.123.042980
- 595 26. Zhang X, He Y, Li X, et al. Circulating 25-hydroxyvitamin D and survival  
596 outcomes of colorectal cancer: evidence from population-based prospective cohorts  
597 and Mendelian randomisation. *British journal of cancer*. May  
598 2024;130(9):1585-1591. doi:10.1038/s41416-024-02643-5
- 599 27. Revez JA, Lin T, Qiao Z, et al. Genome-wide association study identifies 143 loci  
600 associated with 25 hydroxyvitamin D concentration. *Nature communications*. Apr 2  
601 2020;11(1):1647. doi:10.1038/s41467-020-15421-7
- 602 28. Landel V, Annweiler C, Millet P, Morello M, Féron F. Vitamin D, Cognition and  
603 Alzheimer's Disease: The Therapeutic Benefit is in the D-Tails. *Journal of*  
604 *Alzheimer's disease : JAD*. May 11 2016;53(2):419-44. doi:10.3233/jad-150943
- 605 29. Hu L, Shi Y, Zou X, et al. Association of time spent outdoors with the risk of  
606 Parkinson's disease: a prospective cohort study of 329,359 participants. *BMC*  
607 *neurology*. Jan 2 2024;24(1):10. doi:10.1186/s12883-023-03499-7
- 608 30. Giustina A, Bilezikian JP, Adler RA, et al. Consensus Statement on Vitamin D  
609 Status Assessment and Supplementation: Whys, Whens, and Hows. *Endocrine*  
610 *reviews*. Sep 12 2024;45(5):625-654. doi:10.1210/endrev/bnae009

- 611 31. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci,  
612 causal insights, and heritable risk for Parkinson's disease: a meta-analysis of  
613 genome-wide association studies. *The Lancet Neurology*. Dec  
614 2019;18(12):1091-1102. doi:10.1016/s1474-4422(19)30320-5
- 615 32. Kim JJ, Vitale D, Otani DV, et al. Multi-ancestry genome-wide association  
616 meta-analysis of Parkinson's disease. *Nature genetics*. Jan 2024;56(1):27-36.  
617 doi:10.1038/s41588-023-01584-8
- 618 33. Wang T, Geng J, Zeng X, Han R, Huh YE, Peng J. Exploring causal effects of  
619 sarcopenia on risk and progression of Parkinson disease by Mendelian randomization.  
620 *NPJ Parkinson's disease*. Aug 28 2024;10(1):164. doi:10.1038/s41531-024-00782-3
- 621 34. Blauwendraat C, Heilbron K, Vallerga CL, et al. Parkinson's disease age at onset  
622 genome-wide association study: Defining heritability, genetic loci, and  $\alpha$ -synuclein  
623 mechanisms. *Movement disorders : official journal of the Movement Disorder  
624 Society*. Jun 2019;34(6):866-875. doi:10.1002/mds.27659
- 625 35. Iwaki H, Blauwendraat C, Leonard HL, et al. Genomewide association study of  
626 Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. *Movement  
627 disorders : official journal of the Movement Disorder Society*. Dec  
628 2019;34(12):1839-1850. doi:10.1002/mds.27845
- 629 36. Krohn L, Heilbron K, Blauwendraat C, et al. Genome-wide association study of  
630 REM sleep behavior disorder identifies polygenic risk and brain expression effects.  
631 *Nature communications*. Dec 5 2022;13(1):7496. doi:10.1038/s41467-022-34732-5
- 632 37. Chia R, Ray A, Shah Z, et al. Genome sequence analyses identify novel risk loci  
633 for multiple system atrophy. *Neuron*. Jul 3 2024;112(13):2142-2156.e5.  
634 doi:10.1016/j.neuron.2024.04.002
- 635 38. Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies  
636 new loci associated with Lewy body dementia and provides insights into its genetic  
637 architecture. *Nature genetics*. Mar 2021;53(3):294-303.  
638 doi:10.1038/s41588-021-00785-3
- 639 39. Ong JS, Cuellar-Partida G, Lu Y, et al. Association of vitamin D levels and risk  
640 of ovarian cancer: a Mendelian randomization study. *International journal of  
641 epidemiology*. Oct 2016;45(5):1619-1630. doi:10.1093/ije/dyw207
- 642 40. Lu L, Bennett DA, Millwood IY, et al. Association of vitamin D with risk of type  
643 2 diabetes: A Mendelian randomisation study in European and Chinese adults. *PLoS  
644 medicine*. May 2018;15(5):e1002566. doi:10.1371/journal.pmed.1002566
- 645 41. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses  
646 for Robust Causal Inference from Mendelian Randomization Analyses with Multiple



- 647 Genetic Variants. *Epidemiology (Cambridge, Mass)*. Jan 2017;28(1):30-42.  
648 doi:10.1097/ede.0000000000000559
- 649 42. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid  
650 instruments: effect estimation and bias detection through Egger regression.  
651 *International journal of epidemiology*. Apr 2015;44(2):512-25.  
652 doi:10.1093/ije/dyv080
- 653 43. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in  
654 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median  
655 Estimator. *Genetic epidemiology*. May 2016;40(4):304-14. doi:10.1002/gepi.21965
- 656 44. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian  
657 randomization robust to both correlated and uncorrelated pleiotropic effects.  
658 *American journal of human genetics*. Jul 1 2021;108(7):1251-1269.  
659 doi:10.1016/j.ajhg.2021.05.014
- 660 45. Yu K, Chen XF, Guo J, et al. Assessment of bidirectional relationships between  
661 brain imaging-derived phenotypes and stroke: a Mendelian randomization study.  
662 *BMC medicine*. Jul 25 2023;21(1):271. doi:10.1186/s12916-023-02982-9
- 663 46. Zhao J, Ming J, Hu X, Chen G, Liu J, Yang C. Bayesian weighted Mendelian  
664 randomization for causal inference based on summary statistics. *Bioinformatics*  
665 (*Oxford, England*). Mar 1 2020;36(5):1501-1508. doi:10.1093/bioinformatics/btz749
- 666 47. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal  
667 pleiotropy in causal relationships inferred from Mendelian randomization between  
668 complex traits and diseases. *Nature genetics*. May 2018;50(5):693-698.  
669 doi:10.1038/s41588-018-0099-7
- 670 48. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength  
671 requirements for Mendelian randomization studies using multiple genetic variants.  
672 *International journal of epidemiology*. Jun 2011;40(3):740-52.  
673 doi:10.1093/ije/dyq151
- 674 49. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between  
675 imprecisely measured traits using GWAS summary data. *PLoS genetics*. Nov  
676 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 677 50. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V.  
678 High prevalence of hypovitaminosis D status in patients with early Parkinson disease.  
679 *Archives of neurology*. Mar 2011;68(3):314-9. doi:10.1001/archneurol.2011.30
- 680 51. Mayne PE, Burne THJ. Vitamin D in Synaptic Plasticity, Cognitive Function, and  
681 Neuropsychiatric Illness. *Trends in neurosciences*. Apr 2019;42(4):293-306.  
682 doi:10.1016/j.tins.2019.01.003

- 683 52. Moretti R, Morelli ME, Caruso P. Vitamin D in Neurological Diseases: A  
684 Rationale for a Pathogenic Impact. *International journal of molecular sciences*. Jul 31  
685 2018;19(8)doi:10.3390/ijms19082245
- 686 53. Plantone D, Primiano G, Manco C, Locci S, Servidei S, De Stefano N. Vitamin D  
687 in Neurological Diseases. *International journal of molecular sciences*. Dec 21  
688 2022;24(1)doi:10.3390/ijms24010087
- 689 54. Ndayisaba A, Halliday GM, Khurana V. Multiple System Atrophy: Pathology,  
690 Pathogenesis, and Path Forward. *Annual review of pathology*. Oct 15  
691 2024;doi:10.1146/annurev-pathmechdis-051122-104528
- 692 55. Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia  
693 from myelin to cytoplasmic inclusions in multiple system atrophy. *The American*  
694 *journal of pathology*. Oct 2007;171(4):1291-303. doi:10.2353/ajpath.2007.070201
- 695 56. Kaji S, Maki T, Kinoshita H, et al. Pathological Endogenous  $\alpha$ -Synuclein  
696 Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in  
697 Multiple System Atrophy. *Stem cell reports*. Feb 13 2018;10(2):356-365.  
698 doi:10.1016/j.stemcr.2017.12.001
- 699 57. Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and  
700 quantification of oligodendrocyte precursor cells in multiple system atrophy,  
701 progressive supranuclear palsy and Parkinson's disease. *Brain pathology (Zurich,*  
702 *Switzerland)*. May 2013;23(3):263-73. doi:10.1111/j.1750-3639.2012.00637.x
- 703 58. May VE, Ettle B, Poehler AM, et al.  $\alpha$ -Synuclein impairs oligodendrocyte  
704 progenitor maturation in multiple system atrophy. *Neurobiology of aging*. Oct  
705 2014;35(10):2357-68. doi:10.1016/j.neurobiolaging.2014.02.028
- 706 59. Shirazi HA, Rasouli J, Ciric B, Wei D, Rostami A, Zhang GX.  
707 1,25-Dihydroxyvitamin D(3) suppressed experimental autoimmune encephalomyelitis  
708 through both immunomodulation and oligodendrocyte maturation. *Experimental and*  
709 *molecular pathology*. Jun 2017;102(3):515-521. doi:10.1016/j.yexmp.2017.05.015
- 710 60. Gomez-Pinedo U, Cuevas JA, Benito-Martín MS, et al. Vitamin D increases  
711 remyelination by promoting oligodendrocyte lineage differentiation. *Brain and*  
712 *behavior*. Jan 2020;10(1):e01498. doi:10.1002/brb3.1498
- 713 61. Mengozzi M, Hesketh A, Bucca G, Ghezzi P, Smith CP. Vitamins D3 and D2  
714 have marked but different global effects on gene expression in a rat oligodendrocyte  
715 precursor cell line. *Molecular medicine (Cambridge, Mass)*. Apr 9 2020;26(1):32.  
716 doi:10.1186/s10020-020-00153-7
- 717 62. Li N, Yao M, Liu J, et al. Vitamin D Promotes Remyelination by Suppressing  
718 c-Myc and Inducing Oligodendrocyte Precursor Cell Differentiation after Traumatic

- 719 Spinal Cord Injury. *International journal of biological sciences*.  
720 2022;18(14):5391-5404. doi:10.7150/ijbs.73673
- 721 63. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in  
722 European and Middle East countries and strategies to prevent vitamin D deficiency: a  
723 position statement of the European Calcified Tissue Society. *European journal of*  
724 *endocrinology*. Apr 2019;180(4):P23-p54. doi:10.1530/eje-18-0736
- 725

# Mendelian randomization (MR)

## Step 1: Univariable MR exploring the relationship between serum 25(OH)D levels and $\alpha$ -synucleinopathies

### Primary analysis (*Genome-wide IVs selection*)

| Exposure   | Selection of IVs  | Analysis model  | Sensitivity analysis  |
|--|---|---|---|
| 25(OH)D levels (417,580 participants)  | (1) Genome-wide IVs selection:<br>$P < 5 \times 10^{-8}$  | <i>Primary analysis model:</i><br>(1) Inverse variance weighted   | (1) Heterogeneity: Cochran's Q<br>(2) Pleiotropy: MR-Egger intercept;<br>MR-PRESSO global test  |
| <b>Outcome</b><br>(1) iRBD (1,061 cases / 8,386 controls)<br>(2) PD (5,861 cases / 494,487 controls)<br>(3) Age at onset of PD (17,996 cases)<br>(4) PD clinical progression (4,093 cases)<br>(4) MSA (888 cases / 7,128 controls)<br>(5) DLB (2,591 cases / 4,027 controls) | (2) Exclude IVs closely related to the outcome ( $P < 5 \times 10^{-5}$ )<br>(3) LD pruning: $r^2 > 0.001$ , 10000 kb<br>(4) IVs strength: F-statistic $> 10$<br>(5) Eliminating SNPs linked to outcomes using LDtrait database | <i>Secondary analysis model:</i><br>(1) MR Egger<br>(2) Weighted median<br>(3) Constrained maximum likelihood<br>(4) MR Robust adjusted profile score<br>(5) Bayesian Weighted MR | (3) Outliers: MR-PRESSO; MRradial<br>Leave-one-out test<br>(4) Direction: Steiger direction test;<br>Reverse MR analysis<br>(5) FDR correction<br>(6) Statistical power calculation |

### Replication analysis (*Biological function-based IVs selection*)

**Exposure:** 25(OH)D levels

**Outcome:** PD, MSA (IVW-Pval  $< 0.05$  in primary analysis)

**Biological function IVs selection:** Selecting SNPs within four key genes involved in vitamin D metabolism: GC, CYP2R1, DHCR7, and CYP24A1

### Replication analysis (*Sunlight and vitamin D supplementation factors and $\alpha$ -synucleinopathies*)

**Exposure:** *Sunlight and vitamin D supplementation factors:* (1) Time spent outdoors in summer, (2) time spent outdoors in winter, (3) skin colour, (4) use of sun/uv protection, (5) use of vitamin D supplements, (6) no vitamin or mineral supplements

**Outcome:** PD, MSA (IVW-Pval  $< 0.05$  in primary analysis)

## Step 2: Multivariate MR (*Adjusting for genetic pleiotropy*)

**Exposure:** 25(OH)D levels

**Outcome:** MSA (Robust results in primary and replication analyses in step one)

**Adjusted for genetic pleiotropy related to features in the following 3 sets:**

*Set 1: Lifestyle and Socioeconomic Factors*

- Body mass index
- Smoking status
- Alcohol intake frequency
- Physical activity
- Years of schooling

*Set 2: Vitamin D Metabolism Markers*


- Alanine aminotransferase levels
- Creatinine levels
- Parathyroid hormone levels

*Set 3: Chronic Health Conditions*


- Hypertension
- Type 2 diabetes
- Atherosclerotic heart disease
- Stroke
- Gastrointestinal or abdominal disease



A



B



| Exposure             | Covariates   | Outcome | nSNPs | Method     |  | Pval             |
|----------------------|--|---------|-------|------------|--|------------------|
| Serum 25(OH)D levels | Body mass index  | MSA     | 387   | MVMR-IVW   |  | <b>6.44E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>2.80E-03*</b> |
| Serum 25(OH)D levels | Smoking initiation   | MSA     | 143   | MVMR-IVW   |  | <b>3.42E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>1.02E-02*</b> |
| Serum 25(OH)D levels | Alcohol intake frequency   | MSA     | 138   | MVMR-IVW   |  | <b>7.96E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>2.80E-03*</b> |
| Serum 25(OH)D levels | Moderate to vigorous physical activity levels  | MSA     | 101   | MVMR-IVW   |  | <b>2.10E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>2.18E-03*</b> |
| Serum 25(OH)D levels | Years of schooling   | MSA     | 271   | MVMR-IVW   |  | <b>3.07E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>7.08E-03*</b> |
| Serum 25(OH)D levels | Body mass index, smoking initiation, alcohol intake frequency, moderate to vigorous physical activity levels, and years of schooling | MSA     | 380   | MVMR-IVW   |  | <b>7.98E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>8.25E-03*</b> |
| Serum 25(OH)D levels | Alanine aminotransferase levels  | MSA     | 208   | MVMR-IVW   |  | <b>1.76E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>6.71E-03*</b> |
| Serum 25(OH)D levels | Creatinine levels  | MSA     | 305   | MVMR-IVW   |  | <b>6.96E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>4.50E-03*</b> |
| Serum 25(OH)D levels | Parathyroid hormone levels   | MSA     | 91    | MVMR-IVW   |  | <b>2.11E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>2.76E-03*</b> |
| Serum 25(OH)D levels | Alanine aminotransferase, creatinine, and parathyroid hormone levels   | MSA     | 330   | MVMR-IVW   |  | <b>1.19E-02*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>9.78E-03*</b> |
| Serum 25(OH)D levels | Hypertension   | MSA     | 214   | MVMR-IVW   |  | <b>2.24E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>8.16E-04*</b> |
| Serum 25(OH)D levels | Type 2 diabetes  | MSA     | 128   | MVMR-IVW   |  | <b>1.02E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>8.71E-04*</b> |
| Serum 25(OH)D levels | Atherosclerotic heart disease  | MSA     | 95    | MVMR-IVW   |  | <b>1.79E-02*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>4.15E-02*</b> |
| Serum 25(OH)D levels | Stroke   | MSA     | 93    | MVMR-IVW   |  | <b>2.95E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>5.27E-03*</b> |
| Serum 25(OH)D levels | Gastrointestinal or abdominal disease  | MSA     | 94    | MVMR-IVW   |  | <b>3.07E-03*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>3.06E-03*</b> |
| Serum 25(OH)D levels | Hypertension, type 2 diabetes, atherosclerotic heart disease, stroke and gastrointestinal or abdominal disease                       | MSA     | 227   | MVMR-IVW   |  | <b>1.52E-02*</b> |
|                      |  |         |       | MVMR-Egger |  | <b>3.28E-03*</b> |

